Improving safety checks for new eczema (atopic dermatitis) medicines in real-world patients
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations
This work looks for safety problems with new immune-targeting eczema medicines using health records from millions of Americans, including children, pregnant-age women, and other groups often left out of clinical trials.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11289419 on NIH RePORTER |
What this research studies
The team will analyze linked electronic health records and insurance claims covering over 78 million Americans to detect side effects of new systemic immunomodulator drugs for severe atopic dermatitis. They will use advanced causal inference methods to reduce bias and produce more reliable safety estimates that reflect everyday clinical care. The project deliberately includes populations typically excluded from trials, such as children, reproductive-age women, Medicaid beneficiaries, and people with complex health conditions. Results are intended to speed detection of safety signals and support more personalized treatment choices.
Who could benefit from this research
Good fit: People with severe or treatment-resistant atopic dermatitis who are using or considering systemic immunomodulator medicines, including children and those with multiple health problems, are the main focus.
Not a fit: People with mild eczema who are not on systemic therapies or anyone whose medical care is not captured in U.S. insurance or electronic health record databases are less likely to benefit directly.
Why it matters
Potential benefit: Could help patients and clinicians choose safer eczema treatments by revealing rare or subgroup-specific side effects more quickly.
How similar studies have performed: Large pharmacoepidemiology and safety-monitoring efforts have successfully identified drug risks before, and this project applies those established methods to new eczema drugs and underserved groups.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Schneeweiss, Sebastian G. — Brigham and Women's Hospital
- Study coordinator: Schneeweiss, Sebastian G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.